Aptevo Therapeutics Inc.
APVO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3 | $12 |
| % Growth | – | -100% | -74.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $3 | $12 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $14 | $17 | $18 | $19 |
| G&A Expenses | $10 | $12 | $14 | $15 |
| SG&A Expenses | $10 | $12 | $14 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $24 | $29 | $32 | $34 |
| Operating Income | -$25 | -$29 | -$29 | -$21 |
| % Margin | – | – | -919.7% | -174.1% |
| Other Income/Exp. Net | $0 | $10 | $36 | -$8 |
| Pre-Tax Income | -$24 | -$19 | $7 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24 | -$17 | $8 | -$28 |
| % Margin | – | – | 257.8% | -231.5% |
| EPS | -1,747.68 | -46,335 | 51,243 | -197,647 |
| % Growth | 96.2% | -190.4% | 125.9% | – |
| EPS Diluted | -1,747.68 | -46,335 | 51,217 | -197,647 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$24 | -$28 | -$28 | -$20 |
| % Margin | – | – | -890.8% | -164.8% |